Patents by Inventor Etienne De Plaen

Etienne De Plaen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumour rejection antigens
    Patent number: 8519109
    Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: August 27, 2013
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lan-Qing Huang, Aline van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
  • TRYTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS
    Publication number: 20110159017
    Abstract: The unexpected expression of tryptophan 2,3-dioxygenase (TDO2) in cancer cells and tumors has been established. Methods for diagnosing cancer based on the expression of TDO2 are provided, as are methods for treating cancer and inhibiting the growth of cancer cells by inhibiting TDO2, as well as pharmaceutical compositions.
    Type: Application
    Filed: April 10, 2009
    Publication date: June 30, 2011
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Benoit Van Den Eynde, Luc Pilotte, Etienne De Plaen
  • Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
    Patent number: 7923534
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: April 12, 2011
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • TUMOUR REJECTION ANTIGENS
    Publication number: 20090209034
    Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
    Type: Application
    Filed: February 3, 2009
    Publication date: August 20, 2009
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
  • Tumor rejection antigens
    Patent number: 7547439
    Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: June 16, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Method for treating cancer by administering MAGE-derived peptides
    Patent number: 6488932
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: December 3, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
    Patent number: 6379901
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: April 30, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Isolated nonapeptides presented by HLA molecules, and uses thereof
    Patent number: 6222012
    Abstract: The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: April 24, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Etienne De Plaen, Christoph Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde, Pedro Romero
  • Method for determining cancer by determining expression of MAGE-10
    Patent number: 6221593
    Abstract: A correlation between expression of tumor rejection antigen precursor MAGE-10 and cancer has been discovered. The invention is a method for determining presence of cancer in a sample by determining expression of MAGE-10. This determination can be made via, e.g., an immunoassay, an oligonucleotide hybridization assay, or via other standard methodologies.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: April 24, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Francis Brasseur, Donata Rimoldi, Etienne De Plaen
  • Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
    Patent number: 6201111
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 13, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wölfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells
    Patent number: 6034214
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: March 7, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 6001975
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
    Patent number: 5925729
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: July 20, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5856091
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: January 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
    Patent number: 5837476
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 17, 1998
    Assignee: Ludwig Institute
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
    Patent number: RE40089
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: January 24, 1996
    Date of Patent: February 19, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari